Designed to balance
efficacy, safety, and tolerability1,2
Designed to balance
efficacy, safety, and tolerability1,2
*In vitro data. Clinical significance is unknown. The pH range in the bottle is between 3.5 and 5.5.1
See how VUITY™ worksPrimary endpoint was the proportion of patients gaining ≥3 lines in mesopic, high-contrast, binocular distance-corrected near visual acuity (DCNVA) without losing more than 1 line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction at Day 30, Hour 3.1
Change from baseline in photopic, high-contrast, binocular distance-corrected intermediate visual acuity (DCIVA) at Day 30, Hour 3 was a prespecified secondary endpoint.4
NEARLY 9/10
Trial participants [N=76] surveyed would ask their eye doctor for VUITYTM†5
†Assessed by a survey in a subset of participants in the VUITY™ arm of GEMINI 1 and GEMINI 2 studies.
Not an actual patient
Hear from a renowned expert on how VUITY™ may benefit your patients.
VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.
VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.
Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.
Rare cases of retinal detachment have been reported with other miotics when used in susceptible patients and those with pre-existing retinal disease. Patients should be advised to seek immediate medical care with sudden onset of vision loss.
VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.
Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.
To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.
The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia.
Please see full Prescribing Information.
US-PBY-210241
AEs: adverse events. CDVA: corrected distance visual acuity. DCIVA: distance corrected intermediate visual acuity. DCNVA: distance corrected near visual acuity. FDA: Food and Drug administration.
References: 1. VUITY Prescribing Information. 2. Price FW, et al. Ophthalmol Sci. 2021; doi: https://doi.org/10.1016/j.xops.2021.100065. 3. Data on File, ABVRRTI73149. 4. Data on File, ABVRRTI73127. 5. Data on File, REF-87081.